Over the last 12 months, Cogent Biosciences insiders reported no purchases and 7 sales totaling $383.9M across SEC Form 4 filings. 14% of those filings were made under pre-arranged 10b5-1 trading plans.
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | Morris ArleneD | ▼ Sale | 45,510 | $37.12 | $1.7M | -100% | plan · 2 tranches |
| Mar 31, 2026 | Fairmount Funds Management LLCD | ▼ Sale | 7,000,000 | $34.66 | $242.6M | -56% | indirect |
| Jan 22, 2026 | Fairmount Funds Management LLCD | ▼ Sale | 3,500,000 | $36.4 | $127.4M | -38.9% | indirect |
| Dec 26, 2025 | Kearns EvanChief Legal Officer · O | ▼ Sale | 65,000 | $38.7 | $2.5M | -37.3% | — |
| Dec 26, 2025 | Green John L.Chief Financial Officer · O | ▼ Sale | 77,000 | $38.68 | $3.0M | -36.9% | — |
| Dec 26, 2025 | Sachs JessicaChief Medical Officer · O | ▼ Sale | 82,642 | $38.7 | $3.2M | -38.2% | — |
| Dec 26, 2025 | Robinson John EdwardChief Scientific Officer · O | ▼ Sale | 90,000 | $38.74 | $3.5M | -39.1% | — |
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Cogent Biosciences filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $COGT feed.